摘要
目的探讨REG Iα在胃癌组织中的表达状况与Ⅳ期胃癌患者对替吉奥(S-1)联合顺铂(CDDP)化疗敏感性之间的关系。方法选取2010年1月至2011年12月在南阳市第二人民医院收治的不可切除Ⅳ期胃癌患者60例,进行替吉奥(S-1)联合顺铂一线化疗方案治疗。利用免疫组化方法检测治疗前活检组织REG Iα表达,并统计分析REG Iα表达与临床病理特性、疗效间的相关性。结果接受S-1/CDDP一线治疗的60例病人中2(3.3%)例完全缓解,20(33.3%)例部分缓解,治疗有效率36.7%。60例病人的活检样本中,共有16(26.7%)例样本REG Iα表达呈阳性。经统计分析,REG Iα蛋白表达与Ⅳ期胃癌病人的各项临床特征均无相关性,差异无统计学意义(P>0.05)。16例REG Iα表达阳性患者中仅有1(6.3%)例显示出部分缓解,剩余15(93.7%)例患者表现出稳定性或进展性疾病。相应地,在44例REGⅠα表达阴性患者中,2(4.5%)例完全缓解,19(43.2%)例部分缓解,治疗有效率为47.7%。Kaplan-Meier曲线分析显示,REG Iα阴性性患者的TTP、OS显著长于REGⅠα阳性患者,差异具有统计学意义(P<0.05)。结论 REGⅠα是预测晚期胃癌患者S-1/CDDP联合化疗敏感性的预后因子,可以作为晚期胃癌患者个性化化疗方案制定的重要分子标志物,也可能会成为抗癌治疗的潜在药物靶点。
Objective To investigate the relationship between REG Iα and treatment outcomes of chemotherapy S-1 plus cisplatin in patients with stage Ⅳ gastric cancer. Methods A total of 60 patients with unresectable stage Ⅳ gastric cancer in our hospital between January 2010 and January 2011 received first-line chemotherapy with S-1 and cisplatin（S-1 / CDDP） were enrolled. The expression of REG Iα was evaluated immunohistochemically using biopsy samples obtained before chemotherapy, and its relationship to clinicopathological parameters and treatment outcomes was analyzed statistically. Results Among the 60 patients treated with S-1 / CDDP,2（3.3%） showed a complete response and 20（33.3%） showed a partial response, giving an overall response rate of 36.7%. Out of the 60 patients with biopsy samples examined immunohistochemically, 16（26.7%） were positive for REG Iα. And REG Iα expression showed no relationship to any of the clinicopathological features investigated in patients with stage Ⅳ GC（P〉0.05）. Among the 16 patients with REG Iα-positive unresectable GC,only 1（6.3%） showed partial response to S-1 / CDDP treatment, whereas the remaining 15（93.7%） patients showed stable or progressive disease. In contrast, among 44 REG Iα-negative patients, 2（4.5%） had a complete response and 19（43.2%） had a partial response, meaning that 47.7% of REG Iα-negative patients responded to S-1 / CDDP treatment. Kaplan-Meier curves suggested the patients with REG I α-negative GC had a significantly better TTP and OS than those with REG Iα-positive GC（P〈0.01）. Conclusion REG Iαexpression was prognostic for patients with unresectable GC treated with S-1 / CDDP, would be a useful marker for allocation of individualized chemotherapy, and could be a target of anticancer therapy.
出处
《热带医学杂志》
CAS
2015年第8期1034-1037,共4页
Journal of Tropical Medicine
关键词
REG
Iα
替吉奥
顺铂
联合化疗
Ⅳ期胃癌
REG Iα
S-1
Cisplatin
Combined chemotherapy
Stage Ⅳ gastric cancer
